MORRISVILLE, N.C., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (NASDAQ: NOVN) today announced that it intends to offer and sell a combination of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and warrants to purchase shares of its common stock in an underwritten public offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

H.C. Wainwright & Co. is acting as the sole book-running manager for the offering.

The Company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock and/or warrants to purchase common stock to be sold in the offering at the public offering price, less underwriting discounts and commissions.

Novan intends to use the net proceeds from the offering to fund its research and development programs and for general working capital purposes and other operating expenses.

About Novan

Novan, Inc. is a clinical development-stage biotechnology company focused on leveraging nitric oxide’s naturally occurring anti-microbial and immunomodulatory mechanisms of action to treat a range of diseases with significant unmet needs. We believe that our ability to deploy nitric oxide in a solid form, on demand and in localized formulations allows us the potential to improve patient outcomes in a variety of dermatology, women’s health and gastrointestinal diseases.